Constitutively elevated blood serotonin is associated with bone loss and type 2 diabetes in rats

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Erjavec, Igor ^a   Bordukalo Niksic, Tatjana ^a   Brkljacic, Jelena ^a   Grcevic, Danka ^a   Mokrovic, Gordana ^b   Kesic, Maja ^b   Rogic, Dunja ^c   Zavadoski, William ^d   Paralkar, Vishwas M ^d   Grgurevic, Lovorka ^a   Trkulja, Vladimir ^a   Cicin Sain, Lipa ^b   Vukicevic, Slobodan ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c KBC Zagreb   (Croatia)

^d Karos Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PARATHYROID HORMONE; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; MALE; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PANCREAS ISLET BETA CELL; PHENOTYPE; RAT; SEROTONIN BLOOD LEVEL; TRABECULAR BONE; ANIMAL; BLOOD; BONE DISEASE; BONE REMODELING; COMPLICATION; METABOLISM; MOUSE; ORGAN SIZE; OSTEOBLAST; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BONE DISEASES; BONE REMODELING; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; MICE; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS; PHENOTYPE; RATS; SEROTONIN;

EID: 84961144159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150102     Document Type: Article

References (48)

1. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, et al. (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135: 825-837. doi: 10.1016/j.cell.2008.09.059 PMID: 19041748
2. Kode A, Mosialou I, Silva BC, Rached MT, Zhou B, Wang J, et al. (2012) FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. J Clin Invest 122: 3490-3503. doi: 10.1172/JCI64906 PMID: 22945629
3. Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR, et al. (2011) Lrp5functions in bone to regulate bone mass. Nat Med 17: 684-691. doi: 10.1038/nm.2388 PMID: 21602802
4. Brommage R, Liu J, Doree D, Yu W, Powell DR, Melissa Yang Q (2015) Adult Tph2 knockout mice without brain serotonin have moderately elevated spine trabecular bone but moderately low cortical bone thickness. Bonekey Rep 4: 718. doi: 10.1038/bonekey.2015.87 PMID: 26229596
5. Brommage R, Liu J, Hansen GM, Kirkpatrick LL, Potter DG, Sands AT, et al. (2014) High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes. Bone Res 2: 14034. doi: 10.1038/boneres.2014.34 PMID: 26273529
6. Chang MK, Kramer I, Keller H, Gooi JH, Collett C, Jenkins D, et al. (2014) Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res 29: 29-42. doi: 10.1002/jbmr.2059 PMID: 23901037
7. Chabbi-Achengli Y, Coudert AE, Callebert J, Geoffroy V, Cote F, Collet C, et al. (2012) Decreased osteoclastogenesis in serotonin-deficient mice. Proc Natl Acad Sci U S A 109: 2567-2572. doi: 10.1073/pnas.1117792109 PMID: 22308416
8. Frost M, Andersen T, Gossiel F, Hansen S, Bollerslev J, van Hul W, et al. (2011) Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res 26: 1721-1728. doi: 10.1002/jbmr.376 PMID: 21351148
9. Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G, Kassem M (2010) Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res 25: 673-675. doi: 10.1002/jbmr.44 PMID: 20200960
10. Kode A, Obri A, Paone R, Kousteni S, Ducy P, Karsenty G (2014) Lrp5 regulation of bone mass and serotonin synthesis in the gut. Nat Med 20: 1228-1229. doi: 10.1038/nm.3698 PMID: 25375916
11. Cui Y, Niziolek PJ, MacDonald BT, Alenina N, Matthes S, Jacobsen CM, et al. (2014) Reply to Lrp5 regulation of bone mass and gut serotonin synthesis. Nat Med 20: 1229-1230. doi: 10.1038/nm.3697 PMID: 25375917
12. Niziolek PJ, Farmer TL, Cui Y, Turner CH, Warman ML, Robling AG (2011) High-bone-mass-producing mutations in the Wnt signaling pathway resultin distinct skeletal phenotypes. Bone 49: 1010-1019. doi: 10.1016/j.bone.2011.07.034 PMID: 21855668
13. Korvala J, Juppner H, Makitie O, Sochett E, Schnabel D, Mora S, et al. (2012) Mutations in LRP5cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet 13: 26. doi: 10.1186/1471-2350-13-26 PMID: 22487062
14. Lee GS, Simpson C, Sun BH, Yao C, Foer D, Sullivan B, et al. (2014) Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5. J Bone Miner Res 29: 976-981. doi: 10.1002/jbmr.2086 PMID: 24038240
15. Modder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ 3rd, Khosla S (2010) Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 25: 415-422. doi: 10.1359/jbmr.090721 PMID: 19594297
16. Wang Q, Chen D, Nicholson P, Cheng S, Alen M, Mao L (2014) The associations of serum serotonin with bone traits are age-and gender-specific. PLoS One 9: e109028. doi: 10.1371/journal.pone.0109028 PMID: 25279460
17. Rizzoli R, Cooper C, Reginster JY, Abrahamsen B, Adachi JD, Brandi ML, et al. (2012) Antidepressant medications and osteoporosis. Bone 51: 606-613. doi: 10.1016/j.bone.2012.05.018 PMID: 22659406
18. Cicin-Sain L, Froebe A, Bordukalo-Niksic T, Jernej B (2005) Serotonin transporter kinetics in rats selected for extreme values of platelet serotonin level. Life Sci 77: 452-461. PMID: 15894014
19. Jernej B, Cicin-Sain L (1990) Platelet serotonin level in rats is under genetic control. Psychiatry Res 32: 167-174. PMID: 2367601
20. Jernej B, Hranilovic D, Cicin-Sain L (1998) Serotonin transporter on rat platelets: levels of mRNA underlie inherited differences in uptake kinetics. Neurochem Int 33: 519-523. PMID: 10098721
21. Yee CL, Yang R, Bottger B, Finger TE, Kinnamon JC (2001) "Type III" cells of rat taste buds: immunohistochemical and ultrastructural studies of neuron-specific enolase, protein gene product 9.5, and serotonin. J Comp Neurol 440: 97-108. PMID: 11745610
22. Foong JP, Parry LJ, Gwynne RM, Bornstein JC (2010) 5-HT(1A), SST(1), and SST(2) receptors mediate inhibitory postsynaptic potentials in the submucous plexus of the guinea pig ileum. Am J Physiol Gastrointest Liver Physiol 298: G384-394. doi: 10.1152/ajpgi.00438.2009 PMID: 20007849
23. Simic P, Culej JB, Orlic I, Grgurevic L, Draca N, Spaventi R, et al. (2006) Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. J Biol Chem 281: 25509-25521. PMID: 16798745
24. Vukicevic S, Krempien B, Stavljenic A (1987) Effects of 1 alpha, 25-and24R, 25-dihydroxyvitamin D3 on aluminum-induced rickets in growing uremic rats. J Bone Miner Res 2: 533-545. PMID: 3502683
25. Krempien B, Vukicevic S, Vogel M, Stavljenic A, Buchele R (1988) Cellular basis of inflammation-induced osteopenia in growing rats. J Bone Miner Res 3: 573-582. PMID: 3195368
26. Guo J, Liu LJ, Yuan L, Wang N, De W (2011) Expression and localization of paxillin in rat pancreas during development. World J Gastroenterol 17: 4479-4487. doi: 10.3748/wjg.v17.i40.4479 PMID: 22110278
27. Margolis KG, Stevanovic K, Li Z, Yang QM, Oravecz T, Zambrowicz B, et al. (2014) Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut 63: 928-937. doi: 10.1136/gutjnl-2013-304901 PMID: 23749550
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. PMID: 11846609
29. Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel J, Bader M, et al. (2009) Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol 7: e1000229. doi: 10.1371/journal.pbio.1000229 PMID: 19859528
30. Ehret M, Cash CD, Hamon M, Maitre M (1989) Formal demonstration of the phosphorylation of rat brain tryptophan hydroxylase by Ca2+/calmodulin-dependent protein kinase. J Neurochem 52: 1886-1891. PMID: 2542452
31. Mazess RB, Barden H, Ettinger M, Schultz E (1988) Bone density of the radius, spine, and proximal femur in osteoporosis. J Bone Miner Res 3: 13-18. PMID: 3213603
32. Lang T, LeBlanc A, Evans H, Lu Y, Genant H, Yu A (2004) Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res 19: 1006-1012. PMID: 15125798
33. Suwanwalaikorn S, Ongphiphadhanakul B, Braverman LE, Baran DT (1996) Differential responses of femoral and vertebral bones to long-term excessive L-thyroxine administration in adult rats. Eur J Endocrinol 134: 655-659. PMID: 8664988
34. Milne M, Kang MI, Quail JM, Baran DT (1998) Thyroid hormone excess increases insulin-like growth factor I transcripts in bone marrow cell cultures: divergent effects on vertebral and femoral cell cultures. Endocrinology 139: 2527-2534. PMID: 9564868
35. Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, et al. (2010) Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 16: 804-808. doi: 10.1038/nm.2173 PMID: 20581837
36. Diaz-Lopez A, Bullo M, Juanola-Falgarona M, Martinez-Gonzalez MA, Estruch R, Covas MI, et al. (2013) Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study. J Clin Endocrinol Metab 98: 4524-4531. doi: 10.1210/jc.2013-2472 PMID: 24037881
37. Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S (2014) In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 29: 787-795. doi: 10.1002/jbmr.2106 PMID: 24123088
38. Amireault P, Sibon D, Cote F (2013) Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the existence of paracrine/autocrine serotonergic networks. ACS Chem Neurosci 4: 64-71. doi: 10.1021/cn300154j PMID: 23336045
39. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH (2005) Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146: 685-693. PMID: 15539550
40. Smythe GA, Lazarus L (1973) Growth hormone regulation by melatonin and serotonin. Nature 244: 230-231. PMID: 4583097
41. Battaglino R, Fu J, Spate U, Ersoy U, Joe M, Sedaghat L, et al. (2004) Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19: 1420-1431. PMID: 15312242
42. Haden ST, Brown EM, Hurwitz S, Scott J, El-Hajj Fuleihan G (2000) The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol (Oxf) 52: 329-338.
43. Barbosa R, Scialfa JH, Terra IM, Cipolla-Neto J, Simonneaux V, Afeche SC (2008) Tryptophan hydroxylase is modulated by L-type calcium channels in the rat pineal gland. Life Sci 82: 529-535. doi: 10.1016/j.lfs.2007.12.011 PMID: 18221757
44. McKinney J, Knappskog PM, Haavik J (2005) Different properties of the central and peripheral forms of human tryptophan hydroxylase. J Neurochem 92: 311-320. PMID: 15663479
45. Patrick RP, Ames BN (2014) Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J 28: 2398-2413. doi: 10.1096/fj.13-246546 PMID: 24558199
46. Sen Gupta P, Grozinsky-Glasberg S, Drake WM, Akker SA, Perry L, Grossman AB, et al. (2014) Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours? Clin Endocrinol (Oxf) 80: 246-252.
47. Walsh JS, Newell-Price JD, DeBono M, Adaway J, Keevil B, Eastell R (2013) Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome. J Clin Endocrinol Metab 98: 2902-2907. doi: 10.1210/jc.2012-4174 PMID: 23633214
48. Peric M, Dumic-Cule I, Grcevic D, Matijasic M, Verbanac D, Paul R, et al. (2015) The rational use of animal models in the evaluation of novel bone regenerative therapies. Bone 70C: 73-86.